8 BioPharm International eBook February 2020 www.biopharminternational.com
Sourcing Success in Cell
and Gene Therapy Development
As cell and gene therapies become more prominent, industry is seeking
the expertise and capabilities of outsourcing partners to ensure success.
A
s cell and gene therapies are garnering
more interest within the biopharma
industry, demand for adequate manu-
facturing capacity and talent to ensure
success is increasing. To explore how
outsourcing can prove beneficial for cell and gene
therapy (CGT) development, BioPharm International
spoke with Miguel Forte, chief commercialization
officer, ISCT, CEO of Bone Therapeutics, and for-
me r C E O of Z e l lu n a I m mu not he r apy ; A le ngo
Nya may 'a nt u, sc ient i f ic com mu n icat ions ma n-
ager, Polyplus-transfection; and Matthew Lakelin,
vice-president business development and scientific
affairs, TrakCel.
KEY BENEFITS
BioPharm: What are the key benefits of partnering with an
outsourcing organization for the development of CGT?
Forte (Bone Therapeutics): Outsourcing is a key element
of any biotech business and virtually a requirement to be
able to expand and reach out to needed competencies and
resource management. For any biotech, and in particular
for CGT highly innovative processes, the use of outsourcing
enables companies to take advantage of additional required
competencies. Even though the ownership of intellectual
property (IP), know-how and processes, and data should
always remain with the CGT companies, the ability to
use outsourced competencies, in a field where not enough
talent is available, is a very important success factor. In nobeastsofierce
-
Stock.adobe.com
FELICITY THOMAS
Partnerships for Outsourcing Development
